SCHEMBL506180

SCHEMBL506180

CCC(CC)CC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4578588 0.93 TSHR (0.38) TSHRTDP1
SCHEMBL898817 0.82 TSHR (0.30) TSHRTDP1
SCHEMBL12042643 0.82 ALDH1A1 (0.44) TSHRTDP1
SCHEMBL19287575 0.82 ALDH1A1 (0.33) TSHRTDP1
SCHEMBL6293925 0.81 TSHR (0.36) TSHRTDP1
SCHEMBL19937381 0.80
SCHEMBL19333177 0.80 RIPK1 (0.31)
SCHEMBL28580161 0.78
SCHEMBL21161319 0.78
SCHEMBL15183687 0.78 ALDH1A1 (0.36) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2829555-B1 METHOD FOR PRODUCING OLEFIN POLYMER MITSUI CHEMICALS INC (JP) 2018-05-16 EP claimed
CN-104203993-B Process for producing olefin polymer 三井化学株式会社 2016-06-15 CN claimed
US-9315602-B2 Method for producing olefin polymer MITSUI CHEMICALS, INC. (JP) 2016-04-19 US claimed
CN-104672904-A Wear-resistant rubber for tires ZHAOYUAN CITY DONGSHENG LATEX GOODS CO LTD 2015-06-03 CN claimed
US-12616728-B2 Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same SUPER CRITICAL IP, LLC (US) 2026-05-05 US disclosed
US-20250152646-A1 SOLVENTS, METHODS, AND SYSTEMS FOR ISOLATING CANNABINOIDS FROM PLANTS EXTRACTS OR FROM SYNTHETIC PATHWAYS NOEL ARMAND J (US) 2025-05-15 US disclosed
US-12090185-B2 Processes for converting cannabinoids into cannabinoid derivatives and recovering the same SUPER CRITICAL IP, LLC (US) 2024-09-17 US disclosed
US-20240082335-A1 PROCESSES AND SYSTEMS FOR CONVERTING CANNABINOIDS INTO CANNABINOID DERIVATIVES AND ISOLATING THE SAME SUPER CRITICAL IP, LLC 2024-03-14 US disclosed
US-11872259-B2 Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same SUPER CRITICAL IP, LLC (US) 2024-01-16 US disclosed
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-11-09 US disclosed
US-11759491-B2 Solvents, methods, and systems for isolating botanical extracts from plants SUPER CRITICAL IP, LLC (US) 2023-09-19 US disclosed
US-20230032113-A1 SOLVENTS, METHODS, AND SYSTEMS FOR ISOLATING CANNABINOIDS FROM PLANTS EXTRACTS OR FROM SYNTHETIC PATHWAYS SUPER CRITICAL IP, LLC 2023-02-02 US disclosed
US-20030176319-A1 For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts GILEAD PHARMASSET LLC 2003-09-18 US disclosed
US-20030162992-A1 Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde PHARMASSET, INC. 2003-08-28 US disclosed
WO-2003063771-A2 N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS PHARMASSET LTD. (BB) 2003-08-07 WO disclosed
WO-2003051298-A2 PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES PHARMASSET LTD. (BB) 2003-06-26 WO disclosed
WO-2003051306-A2 N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS PHARMASSET LTD. (BB) 2003-06-26 WO disclosed
EP-0091594-B1 AMINOCARBOXYLIC ACID DERIVATIVES Sanraku Incorporated (JP) 1986-01-22 EP disclosed
US-4528397-A Aminocarboxylic acid derivatives SANRAKU-OCEAN CO., LTD. (JP) 1985-07-09 US disclosed
EP-0091594-A1 Aminocarboxylic acid derivatives Sanraku Incorporated (JP) 1983-10-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12616728-B2 Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same CNR2, CNR1, SCD TSHR 2794/4885TDP1 4427/4885
US-20030176319-A1 For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts ENTPD5, CDA, ADA TSHR 4374/4885TDP1 1215/4885
US-20030162992-A1 Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde DERA, DPYD, DHPS TSHR 3766/4885TDP1 630/4885
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF KRAS, NRAS, HRAS TSHR 3862/4885TDP1 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.